共 50 条
- [3] Clinical Trial Diversity in Oncology: FDA Takes Action with Post-Marketing Requirements or Commitments ONCOLOGIST, 2022, 27 (12): : 993 - 997
- [9] POST-MARKETING SURVEILLANCE OF NEW MEDICINES BRITISH MEDICAL JOURNAL, 1977, 2 (6096): : 1218 - 1218
- [10] POST-MARKETING SURVEILLANCE OF MEDICINES IN THE UK PHARMACY INTERNATIONAL, 1981, 2 (09): : 203 - 209